---
document_datetime: 2023-09-21 17:58:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/gliolan-epar-all-authorised-presentations_en.pdf
document_name: gliolan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8356737
conversion_datetime: 2025-12-30 02:28:22.314111
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form      | Route of administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|--------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/07/413/001  | Gliolan           | 30 mg/ml   | Powder for oral solution | Oral use                  | Bottle (glass)        | 1.5 g                     | 1 bottle    |
| EU/1/07/413/002  | Gliolan           | 30 mg/ml   | Powder for oral solution | Oral use                  | Bottle (glass)        | 1.5 g                     | 2 bottles   |
| EU/1/07/413/003  | Gliolan           | 30 mg/ml   | Powder for oral solution | Oral use                  | Bottle (glass)        | 1.5 g                     | 10 bottles  |